ACM
SUPN icon

ADAR1 Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

ADAR1 Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Sell
27,842
-1,800
-6% -$86.5K 0.06% 156
2026
Q1 		$1.53M Sell
29,642
-100
-0.3% -$5.09K 0.09% 131
2025
Q4 		$1.48M Buy
29,742
+15,324
+106% +$745K 0.11% 115
2025
Q3 		$689K Buy
+14,418
New +$581K 0.06% 120

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

ADAR1 Capital Management's SUPN Position: Q2 2026 in Review

ADAR1 Capital Management reduced its Supernus Pharmaceuticals (SUPN) stake by 6.1% in Q2 2026, selling an estimated $86.5K and leaving 27,842 shares worth $1.29M. The position accounts for 0.06% of the portfolio, ranked #156.

ADAR1 Capital Management first reported a position in SUPN in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.53M in Q1 2026. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • ADAR1 Capital Management held 27,842 shares of Supernus Pharmaceuticals worth $1.29M as of Q2 2026.
  • ADAR1 Capital Management sold 1,800 Supernus Pharmaceuticals shares in Q2 2026, an estimated $86.5K.
  • Supernus Pharmaceuticals made up 0.06% of ADAR1 Capital Management's portfolio in Q2 2026, its #156 holding.
  • ADAR1 Capital Management first reported a position in Supernus Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • ADAR1 Capital Management's Supernus Pharmaceuticals position peaked at $1.53M in Q1 2026.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.